![Tom Powles: This seems an ambitious accelerated approval in UC](https://oncodaily.com/pub/uploads/2024/03/tom-e1719421772525.png)
Photo of Tom Powles taken from bartscancer.london
Apr 8, 2024, 15:41
Tom Powles: This seems an ambitious accelerated approval in UC
Tom Powles, Director of Barts Cancer Center, recently shared on X:
“TDXD received FDA accelerated approval in HER2 IHC 3+ treatment-refractory tumors. While HER 1-3+ is common in UC, 3+ is <25% (RR-50% n=16). New treatments are welcome. Ongoing testing is needed. This seems an ambitious accelerated approval in UC.”
Read further.
Source: Tom Powles/X